Compton Capital Management Holding in Amgen (AMGN) Upped by $460,350; Bvf Increased Its Glycomimetics (GLYC) Position by $3.38 Million as Market Value Rose

February 18, 2018 - By Peter Erickson

Compton Capital Management Inc increased its stake in Amgen Inc (AMGN) by 39.52% based on its latest 2017Q3 regulatory filing with the SEC. Compton Capital Management Inc bought 2,475 shares as the company’s stock declined 9.68% while stock markets rallied. The institutional investor held 8,738 shares of the biological products (no diagnostic substances) company at the end of 2017Q3, valued at $1.63 million, up from 6,263 at the end of the previous reported quarter. Compton Capital Management Inc who had been investing in Amgen Inc for a number of months, seems to be bullish on the $132.26B market cap company. The stock decreased 0.03% or $0.05 during the last trading session, reaching $183.55. About 4.37M shares traded or 28.95% up from the average. Amgen Inc. (NASDAQ:AMGN) has risen 5.27% since February 18, 2017 and is uptrending. It has underperformed by 11.43% the S&P500.

Bvf Inc increased its stake in Glycomimetics Inc (GLYC) by 8.74% based on its latest 2017Q3 regulatory filing with the SEC. Bvf Inc bought 259,674 shares as the company’s stock rose 96.61% with the market. The hedge fund held 3.23M shares of the health care company at the end of 2017Q3, valued at $45.19M, up from 2.97M at the end of the previous reported quarter. Bvf Inc who had been investing in Glycomimetics Inc for a number of months, seems to be bullish on the $858.79M market cap company. The stock decreased 1.34% or $0.34 during the last trading session, reaching $25.01. About 469,970 shares traded. GlycoMimetics, Inc. (NASDAQ:GLYC) has risen 81.25% since February 18, 2017 and is uptrending. It has outperformed by 64.55% the S&P500.

Compton Capital Management Inc, which manages about $284.24 million and $222.79 million US Long portfolio, decreased its stake in Apple Inc (NASDAQ:AAPL) by 4,222 shares to 106,511 shares, valued at $16.42 million in 2017Q3, according to the filing.

Since October 9, 2017, it had 0 insider buys, and 3 insider sales for $836,311 activity.

Among 25 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 14 Hold. Therefore 44% are positive. Amgen Inc. had 86 analyst reports since August 3, 2015 according to SRatingsIntel. As per Friday, December 18, the company rating was initiated by Atlantic Securities. The stock has “Buy” rating by Vetr on Friday, August 21. The stock of Amgen Inc. (NASDAQ:AMGN) earned “Buy” rating by Oppenheimer on Tuesday, June 13. As per Monday, June 19, the company rating was maintained by Oppenheimer. The firm earned “Market Perform” rating on Tuesday, September 1 by Raymond James. Oppenheimer maintained the stock with “Buy” rating in Wednesday, August 23 report. Jefferies downgraded the shares of AMGN in report on Wednesday, April 5 to “Hold” rating. The firm has “Overweight” rating by Piper Jaffray given on Thursday, November 5. Oppenheimer maintained it with “Buy” rating and $203.0 target in Wednesday, August 16 report. Argus Research upgraded it to “Buy” rating and $220 target in Tuesday, January 23 report.

Investors sentiment decreased to 0.99 in 2017 Q3. Its down 0.16, from 1.15 in 2017Q2. It dived, as 58 investors sold AMGN shares while 511 reduced holdings. 108 funds opened positions while 453 raised stakes. 555.05 million shares or 0.41% less from 557.32 million shares in 2017Q2 were reported. 417 were reported by Tortoise Investment Mngmt. Howard Capital Management has 6,144 shares. Clifford Swan Invest Counsel Ltd Liability has 60,413 shares for 0.68% of their portfolio. Wagner Bowman Mngmt invested 0.09% of its portfolio in Amgen Inc. (NASDAQ:AMGN). Lazard Asset Mngmt Ltd Liability Company accumulated 0.05% or 130,450 shares. Principal Grp Inc accumulated 1.17M shares. Meiji Yasuda Life Insur Communication has invested 0.32% in Amgen Inc. (NASDAQ:AMGN). Blair William & Il has invested 0.13% in Amgen Inc. (NASDAQ:AMGN). Arcadia Invest Mgmt Corp Mi owns 320 shares for 0.02% of their portfolio. Fulton Commercial Bank Na owns 10,453 shares for 0.15% of their portfolio. Strategic Wealth Advsr Gru Ltd Liability Corporation holds 0.48% of its portfolio in Amgen Inc. (NASDAQ:AMGN) for 15,815 shares. Evercore Wealth Mngmt Ltd Com reported 0.1% of its portfolio in Amgen Inc. (NASDAQ:AMGN). Barrett Asset Management Limited Liability Company holds 0.11% or 7,797 shares. Pennsylvania Company invested in 96,616 shares or 0.87% of the stock. Parsons Mngmt Ri holds 22,642 shares or 0.5% of its portfolio.

Investors sentiment decreased to 1.08 in 2017 Q3. Its down 0.83, from 1.91 in 2017Q2. It fall, as 13 investors sold GLYC shares while 11 reduced holdings. 5 funds opened positions while 21 raised stakes. 28.80 million shares or 2.36% less from 29.49 million shares in 2017Q2 were reported. The Illinois-based Alyeska Investment Gru LP has invested 0.04% in GlycoMimetics, Inc. (NASDAQ:GLYC). Manufacturers Life The accumulated 767 shares or 0% of the stock. Moreover, Bnp Paribas Arbitrage Sa has 0% invested in GlycoMimetics, Inc. (NASDAQ:GLYC) for 72 shares. Perigon Wealth Ltd Llc has invested 0% of its portfolio in GlycoMimetics, Inc. (NASDAQ:GLYC). Citadel invested in 58,422 shares or 0% of the stock. 116,629 were reported by Susquehanna Grp Incorporated Llp. Blackrock Inc holds 0% or 524,610 shares in its portfolio. First Personal Fin Svcs stated it has 1,892 shares or 0.01% of all its holdings. Moreover, Bridgeway Cap Management has 0.01% invested in GlycoMimetics, Inc. (NASDAQ:GLYC). Geode Mgmt Limited Liability Company owns 156,952 shares. Fmr Limited Company reported 1.48 million shares. Redmile Group Limited Co holds 0.84% in GlycoMimetics, Inc. (NASDAQ:GLYC) or 1.21M shares. Eam Invsts Limited Com reported 0.69% in GlycoMimetics, Inc. (NASDAQ:GLYC). Baker Bros Advisors Limited Partnership has invested 0.06% in GlycoMimetics, Inc. (NASDAQ:GLYC). Wellington Group Llp holds 3.49M shares or 0.01% of its portfolio.

Since September 18, 2017, it had 0 insider buys, and 2 insider sales for $56,020 activity.

Bvf Inc, which manages about $999.89M and $786.73 million US Long portfolio, decreased its stake in Aduro Biotech Inc by 115,236 shares to 184,764 shares, valued at $1.97 million in 2017Q3, according to the filing. It also reduced its holding in Pieris Pharmaceuticals Inc by 505,371 shares in the quarter, leaving it with 2.99 million shares, and cut its stake in Chemocentryx Inc (NASDAQ:CCXI).

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>